Company news
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) news
Every Phio Pharmaceuticals Corp. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 11, 2026
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
August 11, 2026
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
August 6, 2026
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roa...
July 22, 2026
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
July 21, 2026
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
July 15, 2026
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office ...
June 25, 2026
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
June 24, 2026
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
June 18, 2026
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesd...
May 12, 2026
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
May 7, 2026
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesda...
April 13, 2026
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
April 9, 2026
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
March 30, 2026
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 fo...
March 23, 2026
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
March 16, 2026
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
March 10, 2026
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
March 10, 2026
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
March 5, 2026
Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company
February 23, 2026
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
February 19, 2026
Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
February 10, 2026
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
January 26, 2026
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
January 20, 2026
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
January 15, 2026
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
December 23, 2025
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
November 25, 2025
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
November 17, 2025
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 13, 2025
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762
November 7, 2025
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program
November 7, 2025
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds
November 3, 2025
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial
November 3, 2025
Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director
October 31, 2025
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
October 21, 2025
Phio Pharmaceuticals to Present at the Life Sciences Future Conference
September 18, 2025
Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
July 25, 2025
Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort
July 25, 2025
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance
July 25, 2025
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial t...
June 25, 2025
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
June 24, 2025
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
June 6, 2025
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
May 19, 2025
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
May 7, 2025
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth ...
April 9, 2025
Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
April 3, 2025
Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
March 31, 2025